Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sisunatovir Safety, PK, and Palatability in Healthy Adults
NCT05712460Phase 1Completed
- Sponsor
- Pfizer
- Start
- Feb 2023
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sisunatovir in respiratory syncytial virus infection (RSV) (5 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events, Number of Participants With Clinical Laboratory Abnormalities at Day 5 and 2 more. Started Feb 2023; status: completed.
02
Drugs
sisunatovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05712460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05712460.